News · 26 weeks39-17%
2025-12-142026-06-07
Mix3090d
- SEC Filings8(27%)
- Insider8(27%)
- Earnings6(20%)
- Other5(17%)
- Leadership3(10%)
Latest news
25 items- PRNEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18thLANGHORNE, Pa., June 04, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the Planet MicroCap Conference on June 16 – 18, 2026, in Las Vegas, NV. Planet MicroCap Las Vegas 2026Dates: June 16-18, 2026Location: Bellagio Hotel & Casino, Las Vegas, NVBooth: #517Presentation Day and Time: Wednesday, June 17, 2026, at 1:30 P.M. PTPresentation Location: Track 3 - Da Vinci 3Webcast: https://ir.nexgel.com/news-events/events-presentat
- INSIDERChief Executive Officer Levy Adam R. sold $1,172 worth of shares (2,000 units at $0.59), decreasing direct ownership by 0.58% to 342,692 units (SEC Form 4)4 - NEXGEL, INC. (0001468929) (Issuer)
- INSIDERChief Executive Officer Levy Adam R. sold $7,834 worth of shares (13,000 units at $0.60), decreasing direct ownership by 4% to 344,692 units (SEC Form 4)4 - NEXGEL, INC. (0001468929) (Issuer)
- SECSEC Form PRE 14A filed by NexGel IncPRE 14A - NEXGEL, INC. (0001468929) (Filer)
- PRNEXGEL Reports Positive Data from Randomized Single-Center IRB Study to Evaluate the Effectiveness and Safety of a Hydrogel Laser Treatment Patch in Laser Hair Removal with a 95.6% Reduction in Plume ConcentrationThe study concluded that NEXGEL's hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control The study was published in Lasers in Surgery and Medicine, 2026 LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical study, funded
- INSIDERSEC Form 4 filed by Director Henry Scott Robert4 - NEXGEL, INC. (0001468929) (Issuer)
- INSIDERSEC Form 4 filed by Director Kieser Brian Joseph4 - NEXGEL, INC. (0001468929) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Levy Adam R.4 - NEXGEL, INC. (0001468929) (Issuer)
- INSIDERSEC Form 3 filed by new insider Harris Kevin Mcclain3 - NEXGEL, INC. (0001468929) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kieser Brian Joseph3 - NEXGEL, INC. (0001468929) (Issuer)
- SECSEC Form 10-Q filed by NexGel Inc10-Q - NEXGEL, INC. (0001468929) (Filer)
- PRNEXGEL Appoints Dave Hazard as Vice President of Sales for BIONX SurgicalAppointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL. Mr. Hazard brings more than 13 years of sales leadership across orthopedics, spine, and biologics, and joins BIONX Surgical at a
- SECNexGel Inc filed SEC Form 8-K: Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- PRNEXGEL To Report First Quarter 2026 Financial Results on May 15thManagement Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2026 ended March 31, 2026, on Friday, May 15, 2026. Following the release of its financial results, the Company will host a conference call at 12:00 P.M. ET on the same day. First Quarter 2026 Financial Results Conference Call:Date: May 15, 2026Time: 12:00 P.M
- INSIDERSEC Form 3 filed by new insider Blackman Ian Howard3 - NEXGEL, INC. (0001468929) (Issuer)
- PRNEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience™, to Board of DirectorsSequence LifeScienceTM Led Financing to Close on Acquisition of Celularity with Strategic Investment of $5.5 Million LANGHORNE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Brian J. Kieser, CPA, and Kevin Harris, CFA, to the Board of Directors. Mr. Kieser is currently the CEO and Mr. Harris is the COO of Sequence LifeScienceTM, which recently led the financing to close on the acquisition of Celularity Inc.'s degenerative dise
- SECAmendment: SEC Form 10-K/A filed by NexGel Inc10-K/A - NEXGEL, INC. (0001468929) (Filer)
- SECNexGel Inc filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- PRNEXGEL Appoints Ian Blackman as Chief Financial OfficerVeteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Ian Blackman, CPA, as Chief Financial Officer. Mr. Blackman will help to advance the closing of the definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc., ("Celularity")
- SECNexGel Inc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - NEXGEL, INC. (0001468929) (Filer)
- SECNexGel Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - NEXGEL, INC. (0001468929) (Filer)
- PRNEXGEL New Strategic Partner, Sequence LifeScience™, Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative Disease SegmentTransaction expected to approximately triple NEXGEL's annual revenue to approximately $35 million and is expected to be immediately accretive to profitability Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Forms BioNX Surgical, a division of NEXGEL LANGHORNE, Pa. , April 21, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consume
- PRNEXGEL Moves Forward Shareholder Update Call to Discuss Celularity Transaction on April 21st at 4:30 P.M. ETLANGHORNE, Pa., April 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it is moving up its shareholder update conference call from Thursday, April 23rd to Tuesday, April 21st, 2026, at 4:30 P.M. ET. Shareholder Update Call Details:Date: April 21, 2026Time: 4:30 P.M. ETLive Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International)Webcast: Events and Presentations About NEXGEL, Inc.NEXGEL is a leading provider of healthcare, beauty, and over-th
- PRNEXGEL Reschedules Shareholder Update Conference Call to April 23rd at 4:30 P.M. ET to Provide Update on Celularity TransactionLANGHORNE, Pa., April 15, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its shareholder update conference call to April 23, 2026, at 4:30 P.M. ET. While there is no assurance that the Celularity transaction will close, the Company will not be financing the transaction under its previously announced Securities Purchase Agreement with a certain institutional investor. The Company is in the process of negotiating a new agreement with a diffe
- PRNEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity TransactionLANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its shareholder update conference call to April 15, 2026, at 4:30 P.M. ET. While there is no assurance that the Celularity transaction will close, the Company will not be financing the transaction under its previously announced Securities Purchase Agreement with a certain institutional investor. The Company is in the process of negotiating a new agreement with a diffe
NXGL FAQ
7 questionsWhat does NexGel Inc do?
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.Where does NXGL stock trade?
NexGel Inc (NXGL) is listed on NASDAQ.What sector and industry is NXGL in?
NexGel Inc operates in the Health Care sector, Medical/Dental Instruments industry.When did NexGel Inc go public?
NexGel Inc (NXGL) completed its IPO in 2021.What are analysts saying about NXGL?
NexGel Inc has had 1 recent analyst action on file. The most recent action was from Maxim Group: Buy with a $600.00 price target on 2022-02-25. Recent price targets cluster around $600.00.What companies are similar to NXGL?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare NXGL side-by-side with any of them on Quantisnow.How can I track NXGL on Quantisnow?
Quantisnow aggregates NexGel Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NXGL to receive live email and push alerts on every new disclosure.